Integra Announces Pricing of Senior Secured Notes

The refinancing includes secured debt carrying a 9.500% rate and maturing in 2033.

Rhea-AI Summary

Integra LifeSciences Holdings (IART) priced $450 million of senior secured notes as part of a broader refinancing transaction. The notes carry a 9.500% rate and mature in 2033. Closing is expected on or about October 19, 2026. The company intends to combine net proceeds with borrowings under new credit facilities to refinance existing credit facilities and pay related fees and expenses.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Priced offering would provide $450 million in principal funding for the broader refinancing. 43% of market cap

Negative

• Major point$450 million of senior secured notes carry a 9.500% rate and mature in 2033. 43% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.New credit facility borrowings are also planned to refinance existing facilities.
• Minor point. Forward-looking: it has not happened yet and may not happen.Related fees and expenses will be paid using the planned refinancing funding.

News Explained

Integra’s priced $450 million notes are general senior secured obligations and carry guarantees from wholly owned domestic subsidiaries that guarantee its senior secured credit facilities.

Key Figures

Aggregate principal amount: $450,000,000 Interest rate: 9.500% Maturity: 2033 +1 more

Aggregate principal amount

$450,000,000

Senior secured notes

Interest rate

9.500%

Senior secured notes

Maturity

2033

Notes due

Expected closing

On or about October 19, 2026

Subject to customary closing conditions

Historical Context

1 past event · Latest: Oct 02

1 event

1. Oct 02

   Senior secured loan

   24h Move

   -21.2%

   Launched a proposed $600 million seven-year senior secured Term Loan B within the broader refinancing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

senior secured notes, qualified institutional buyers, rule 144a, regulation s

4 terms

senior secured notes financial

"pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes"

Senior secured notes are loans a company sells to investors that are backed by specific assets and given first priority for repayment if the company defaults. Because they have a claim on collateral and are paid before other debts, they usually offer lower risk and correspondingly lower interest than unsecured debt; investors use them to judge how safe repayment and recovery of principal might be, like holding a mortgage instead of an unsecured credit card balance.

qualified institutional buyers financial

"offered only to persons reasonably believed to be qualified institutional buyers"

Qualified institutional buyers are large organizations, like big investment firms or banks, that are allowed to buy certain types of investment opportunities not available to everyday investors. Their size and experience matter because it ensures they understand and can handle complex financial deals, making markets more efficient and secure.

rule 144a regulatory

"reliance on the exemption from registration provided by Rule 144A"

Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.

regulation s regulatory

"in compliance with Regulation S of the Securities Act"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the “Company”) today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured credit facilities. The sale of the Notes is expected to close on or about October 19, 2026, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering of Notes, together with borrowings under new credit facilities, to refinance its existing credit facilities and pay fees and expenses in connection with the foregoing.

The offering is part of a broader refinancing transaction.

The Notes and the related guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction. The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A of the Securities Act and to certain non-U.S. persons outside of the United States in compliance with Regulation S of the Securities Act.

This press release is being issued pursuant to Rule 135c of the Securities Act and is neither an offer to sell, nor a solicitation of an offer to buy, any of the securities mentioned above and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offer of the securities mentioned above will be made only by means of a private offering memorandum.

About Integra

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” “plan,” “anticipate,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this press release include, but are not limited to, the expectations, plans and prospects for the Company, including whether the Company will consummate the offering of the Notes on the expected terms or at all, the anticipated use of proceeds of the offering of the Notes, market and other general economic conditions, and other risks identified under the heading “Risk Factors” included in item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Integra's senior secured notes offering?

Integra priced $450 million in aggregate principal amount of senior secured notes carrying a 9.500% rate and due in 2033. The offering is part of a broader refinancing transaction.

When is Integra's senior secured notes offering expected to close?

The sale is expected to close on or about October 19, 2026, subject to customary closing conditions.

Which subsidiaries will guarantee Integra's senior secured notes?

The notes will be guaranteed by Integra's wholly-owned domestic subsidiaries that are guarantors under its senior secured credit facilities. The notes will be general senior secured obligations of the company.

Who was eligible to buy Integra's senior secured notes?

The notes were offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A and certain non-U.S. persons outside the United States under Regulation S. The notes and related guarantees have not been, and will not be, registered under the Securities Act or other applicable jurisdictional securities laws.